Translational Accelerator: AV-CTIP Device Innovation Award

Translational research in rare and complex conditions often stalls between promising concepts and patient-ready solutions. The Additional Ventures Translational Accelerator was developed to help researchers overcome the “valley of death” in single ventricle translational research. By removing early stage roadblocks and equipping researchers with both funding and strategic expertise, the Accelerator helps translate high-potential discoveries to clinical realities. The Accelerator supports two independent award streams that each target a critical area of need in translational science: therapeutics and devices.

The AV-CTIP Device Innovation Award underscores our commitment to tackling device innovation as a critical frontier in single ventricle care.

The AV-CTIP Device Innovation Award

Medical devices play a vital role in single ventricle care, but virtually no medical devices are specifically designed or engineered to meet the needs of single ventricle patients. To close this gap, Additional Ventures (AV), in partnership with the Consortium for Technology & Innovation in Pediatrics (CTIP), is launching the AV-CTIP Device Innovation Award. This initiative advances early-stage device concepts purpose-built for single ventricle patients across every stage of treatment. By supporting early-stage device innovators, this program seeks to fill critical gaps in care for single ventricle patients, catalyze clinical translation, and ultimately improve long term outcomes for this high-need community.

About the Partnership

This award combines Additional Ventures’ commitment to revolutionizing treatment and care for individuals with single ventricle heart disease with CTIP’s expertise in medical device development and commercialization. Together, we are providing the financial support, technical resources, and disease-specific expertise innovators need to move high-potential technologies from concept toward clinical impact.

Funding and Support

Awardees will be eligible for:

  • Up to $1M in milestone-driven funding, up to approximately 3 years in total, with access to advising, services, and support throughout the award term.
  • Tailored technical and business support through CTIP — including expert coaching, strategic connections, and access to consulting and service providers.
  • Supplemental resources to advance projects through critical phases of device development, from early prototyping to clinical readiness.

What Fits

While surgical intervention has improved survival in single ventricle heart disease, patients still experience progressive complications. Few medical or device-based innovations address the unique physiological challenges or downstream complications of single ventricle heart disease.

We are particularly interested in technologies that can:

  • Improve or augment the Fontan physiology, including support for low-pressure pulmonary flow, single-ventricle function, or optimized conduit/shunt performance
  • Enable earlier intervention in failing Fontan patients or improve candidacy for transplantation
  • Prevent, monitor, or treat sequelae such as lymphatic congestion, liver fibrosis, arrhythmias, or protein-losing enteropathy
  • Support quality of life and daily function across pediatric and adult populations
  • Deliver diagnostic or monitoring capabilities that provide actionable insights into Fontan performance and end-organ health

Who May Apply

Teams affiliated with U.S.-based academic institutions and companies are invited to apply. At minimum, teams must include a coordinating project lead, project manager, and appropriate clinical and technical expertise to support the success of their asset.

Applicants are welcome to include additional key personnel critical to the success of the project. These may include, but are not limited to:

  • Co-investigators
  • Clinical or technical collaborators
  • Regulatory, reimbursement, or commercialization experts
  • Consultants or contracted specialists in relevant areas (e.g., human factors, design controls, biostatistics)

All additional personnel should have a clearly defined role and level of effort. Letters of support or biosketches may be requested to document and assess their involvement.

 

Award Amount
Up to $1M in milestone-driven funding, up to approximately 3 years in total, with access to advising, services, and support throughout the award term.

 

Deadlines

Letters of intent due:
November 6, 2025

 

 

Full proposal invitation:
Mid-December, 2025

 

Notification of awards:
By June 30, 2026

 

Funding begins:
September 1, 2026